Skip to content
Back to resident companies

XGenomes

Investment areas

  • Biotech / Life Sciences
Founders & Leadership
Kalim Mir
Headquarters
Cambridge, MA

Sequencing reinvented to detect the molecular signals of health, disease and aging.

The Tough Tech problem we are solving

Our tough tech problem is how to sequence (read) the chemically encoded information in DNA accurately, rapidly and economically, to make a material difference to our health and well-being thought life. Methods in use today are failing to convert molecular knowledge into practical affordable everyday solutions for healthcare.

About our solution

XGenomes’ radical new technology changes the paradigm of how DNA is sequenced. Existing technologies read the information encoded in DNA as ‘letters’, XGenomes read ‘words’. A repertoire of oligonucleotides probes bind rapidly repetitively, and sequence-specifically to ‘words’ in unamplified single molecules of DNA, with the potential to simultaneously read billions of molecules arrayed at high density in a flow cell. The technology will be offered as a streamlined and extraordinarily versatile sample-to-sequence solution under an economic model that will drive uptake in healthcare and precision medicine.